{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:53:05Z","timestamp":1776772385931,"version":"3.51.2"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24KJ1943"],"award-info":[{"award-number":["24KJ1943"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22K06131"],"award-info":[{"award-number":["22K06131"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K06135"],"award-info":[{"award-number":["23K06135"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JPMJS2123"],"award-info":[{"award-number":["JPMJS2123"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","award":["K06131,24KJ1943"],"award-info":[{"award-number":["K06131,24KJ1943"]}],"id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.intimp.2026.116284","type":"journal-article","created":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T21:52:17Z","timestamp":1769896337000},"page":"116284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeting DDX5 using FL118 suppresses mTOR signaling and tumorigenicity in JAK2V617F-driven myeloproliferative neoplasms"],"prefix":"10.1016","volume":"173","author":[{"given":"Kengo","family":"Takeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Tago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Funakoshi-Tago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2026.116284_bb0005","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116284_bb0010","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood.2022017578","article-title":"Genetic basis and molecular profiling in myeloproliferative neoplasms","volume":"141","author":"Luque Paz","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116284_bb0015","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.116284_bb0020","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116284_bb0025","doi-asserted-by":"crossref","first-page":"18962","DOI":"10.1073\/pnas.0509714102","article-title":"Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation","volume":"102","author":"Lu","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.intimp.2026.116284_bb0030","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1128\/MCB.01447-07","article-title":"Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity","volume":"28","author":"Funakoshi-Tago","year":"2008","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.intimp.2026.116284_bb0035","first-page":"423","article-title":"The role of erythropoietin receptor tyrosine phosphorylation in erythropoietin-induced proliferation","volume":"11","author":"Damen","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.intimp.2026.116284_bb0040","doi-asserted-by":"crossref","first-page":"5292","DOI":"10.1073\/pnas.92.12.5292","article-title":"Distinct regions of c-Mpl cytoplasmic domain are coupled to the JAK-STAT signal transduction pathway and Shc phosphorylation","volume":"92","author":"Gurney","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.intimp.2026.116284_bb0045","doi-asserted-by":"crossref","first-page":"40702","DOI":"10.1074\/jbc.M307182200","article-title":"Roles for an Epo receptor Tyr-343 Stat5 pathway in proliferative co-signaling with kit","volume":"278","author":"Li","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2026.116284_bb0050","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1002\/j.1460-2075.1995.tb07284.x","article-title":"Thrombopoietin activates a STAT5-like factor in hematopoietic cells","volume":"14","author":"Pallard","year":"1995","journal-title":"EMBO J."},{"key":"10.1016\/j.intimp.2026.116284_bb0055","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1128\/MCB.15.2.593","article-title":"Interaction of Shc with Grb2 regulates association of Grb2 with mSOS","volume":"15","author":"Ravichandran","year":"1995","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.intimp.2026.116284_bb0060","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1182\/blood.V96.3.941","article-title":"A member of Forkhead family transcription factor, FKHRL1, is one of the downstream molecules of phosphatidylinositol 3-kinase-Akt activation pathway in erythropoietin signal transduction","volume":"96","author":"Kashii","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116284_bb0065","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1074\/jbc.M109.040733","article-title":"STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant","volume":"285","author":"Funakoshi-Tago","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2026.116284_bb0070","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1074\/jbc.M116.749465","article-title":"Three tyrosine residues in the erythropoietin receptor are essential for Janus kinase 2 V617F mutant-induced tumorigenesis","volume":"292","author":"Ueda","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.intimp.2026.116284_bb0075","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.cellsig.2011.01.009","article-title":"Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation","volume":"23","author":"Kamishimoto","year":"2011","journal-title":"Cell. Signal."},{"key":"10.1016\/j.intimp.2026.116284_bb0080","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116284_bb0085","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.116284_bb0090","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1182\/blood.2024025441","article-title":"Hit the road JAK, don't P-STAT, stem more!","volume":"144","author":"Ng","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116284_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1384509","article-title":"Mathematical modelling of stem and progenitor cell dynamics during ruxolitinib treatment of patients with myeloproliferative neoplasms","volume":"15","author":"Boklund","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2026.116284_bb0100","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/339562a0","article-title":"RNA helicase activity associated with the human p68 protein","volume":"339","author":"Hirling","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.intimp.2026.116284_bb0105","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1093\/nar\/gkm058","article-title":"Redundant role of DEAD box proteins p68 (Ddx5) and p72\/p82 (Ddx17) in ribosome biogenesis and cell proliferation","volume":"35","author":"Jalal","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.intimp.2026.116284_bb0110","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.1128\/MCB.22.15.5443-5450.2002","article-title":"p68 RNA helicase is an essential human splicing factor that acts at the U1 snRNA-5\u2032 splice site duplex","volume":"22","author":"Liu","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.intimp.2026.116284_bb0115","doi-asserted-by":"crossref","first-page":"7734","DOI":"10.1038\/sj.onc.1204976","article-title":"Overexpression and poly-ubiquitylation of the DEAD-box RNA helicase p68 in colorectal tumours","volume":"20","author":"Causevic","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2026.116284_bb0120","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.gendis.2022.02.008","article-title":"DEAD-box RNA helicases with special reference to p68: unwinding their biology, versatility, and therapeutic opportunity in cancer","volume":"10","author":"Tabassum","year":"2022","journal-title":"Genes Dis."},{"key":"10.1016\/j.intimp.2026.116284_bb0125","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s13045-018-0656-7","article-title":"The lncRNA NEAT1 activates Wnt\/\u03b2-catenin signaling and promotes colorectal cancer progression via interacting with DDX5","volume":"11","author":"Zhang","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2026.116284_bb0130","first-page":"51","article-title":"The art of writing a scientific article","volume":"163","author":"Van der Geer","year":"2020","journal-title":"J. Sci. Commun."},{"key":"10.1016\/j.intimp.2026.116284_bb0135","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/onc.2013.561","article-title":"Arf tumor suppressor disrupts the oncogenic positive feedback loop including c-Myc and DDX5","volume":"34","author":"Tago","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2026.116284_bb0140","doi-asserted-by":"crossref","first-page":"7938","DOI":"10.1158\/0008-5472.CAN-08-0932","article-title":"The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer","volume":"68","author":"Clark","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2026.116284_bb0145","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1126\/science.6177045","article-title":"HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression","volume":"216","author":"Martin","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.intimp.2026.116284_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110537","article-title":"The indispensable role of the RNA helicase DDX5 in tumorigenesis induced by the myeloproliferative neoplasm-associated JAK2V617F mutant","volume":"102","author":"Takeda","year":"2023","journal-title":"Cell. Signal."},{"key":"10.1016\/j.intimp.2026.116284_bb0155","article-title":"DDX5 is required for JAK2V617F-induced cell proliferation and tumorigenesis independent of its RNA helicase activity","volume":"138","author":"Takeda","year":"2025","journal-title":"Cell. Signal."},{"key":"10.1016\/j.intimp.2026.116284_bb0160","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.881","article-title":"FL118, acting as a 'molecular glue degrader', binds to, dephosphorylates and degrades the oncoprotein DDX5 (p68) to control c-Myc, Survivin and mutant Kras against colorectal and pancreatic cancer with high efficacy","volume":"12","author":"Ling","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.intimp.2026.116284_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045571","article-title":"A novel small molecule FL118 that selectively inhibits Survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity","volume":"7","author":"Ling","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.intimp.2026.116284_bb0170","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.3390\/ijms25073693","article-title":"FL118 is a potent therapeutic agent against chronic myeloid leukemia resistant to BCR-ABL inhibitors through targeting RNA helicase DDX5","volume":"25","author":"Takeda","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.intimp.2026.116284_bb0175","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","article-title":"Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis","volume":"18","author":"Mascarenhas","year":"2012","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"key":"10.1016\/j.intimp.2026.116284_bb0180","doi-asserted-by":"crossref","first-page":"7484","DOI":"10.1128\/MCB.25.17.7484-7493.2005","article-title":"ATPase\/helicase activities of p68 RNA helicase are required for pre-mRNA splicing but not for assembly of the spliceosome","volume":"25","author":"Lin","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.intimp.2026.116284_bb0185","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2018100986","article-title":"Arginine methylation of the DDX5 helicase RGG\/RG motif by PRMT5 regulates resolution of RNA:DNA hybrids","volume":"38","author":"Mersaoui","year":"2019","journal-title":"EMBO J."},{"key":"10.1016\/j.intimp.2026.116284_bb0190","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cell.2006.08.036","article-title":"P68 RNA helicase mediates PDGF-induced epithelial mesenchymal transition by displacing Axin from beta-catenin","volume":"127","author":"Yang","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2026.116284_bb0195","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/febs.16618","article-title":"Identification of DDX5 as an indispensable activator of the glucocorticoid receptor in adipocyte differentiation","volume":"290","author":"Hokimoto","year":"2023","journal-title":"FEBS J."},{"key":"10.1016\/j.intimp.2026.116284_bb0200","doi-asserted-by":"crossref","first-page":"6708","DOI":"10.1158\/0008-5472.CAN-11-1472","article-title":"RNA helicase DDX5 is a p53-independent target of ARF that participates in ribosome biogenesis","volume":"71","author":"Saporita","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2026.116284_bb0205","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.devcel.2006.08.003","article-title":"The RNA helicases p68\/p72 and the noncoding RNA SRA are coregulators of MyoD and skeletal muscle differentiation","volume":"11","author":"Caretti","year":"2006","journal-title":"Dev. Cell"},{"key":"10.1016\/j.intimp.2026.116284_bb0210","doi-asserted-by":"crossref","first-page":"4053","DOI":"10.1038\/onc.2009.261","article-title":"The DEAD-box protein p72 regulates ERalpha\u2212\/oestrogen-dependent transcription and cell growth, and is associated with improved survival in ERalpha-positive breast cancer","volume":"28","author":"Wortham","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2026.116284_bb0215","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1126\/science.1231499","article-title":"RNA helicase DDX3 is a regulatory subunit of casein kinase 1 in Wnt-\u03b2-catenin signaling","volume":"339","author":"Cruciat","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.intimp.2026.116284_bb0220","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/hep.32651","article-title":"RNA helicase DEAD-box protein 5 alleviates nonalcoholic steatohepatitis progression via tethering TSC complex and suppressing mTORC1 signaling","volume":"77","author":"Zhang","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.intimp.2026.116284_bb0225","first-page":"370","article-title":"Topoisomerase I (Top1): a major target of FL118 for its antitumor efficacy or mainly involved in its side effects of hematopoietic toxicity?","volume":"7","author":"Li","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.intimp.2026.116284_bb0230","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.116284_bb0235","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of Fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.intimp.2026.116284_bb0240","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: a randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol."},{"issue":"16","key":"10.1016\/j.intimp.2026.116284_bb0245","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1080\/14796694.2025.2511564","article-title":"Indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis","volume":"21","author":"Masarova","year":"2025","journal-title":"Future oncology (London, England)"},{"key":"10.1016\/j.intimp.2026.116284_bb0250","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1182\/blood-2006-04-017392","article-title":"Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera","volume":"108","author":"Ishii","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116284_bb0255","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1182\/blood-2012-01-402396","article-title":"Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-\u03b1 in a murine model of polycythemia vera","volume":"120","author":"Mullally","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2026.116284_bb0260","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2026.116284_bb0265","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12943-015-0362-9","article-title":"FL118, a novel camptothecin derivative, is insensitive to ABCG2 expression and shows improved efficacy in comparison with irinotecan in colon and lung cancer models with ABCG2-induced resistance","volume":"14","author":"Westover","year":"2015","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.intimp.2026.116284_bb0270","first-page":"3676","article-title":"FL118, a novel Survivin inhibitor, wins the battle against drug-resistant and metastatic lung cancers through inhibition of cancer stem cell-like properties","volume":"9","author":"Wang","year":"2017","journal-title":"Am. J. Transl. Res."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692600127X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692600127X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T11:19:01Z","timestamp":1776770341000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692600127X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":54,"alternative-id":["S156757692600127X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116284","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting DDX5 using FL118 suppresses mTOR signaling and tumorigenicity in JAK2V617F-driven myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2026.116284","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116284"}}